Chronic Kidney Disease-associated Pruritus Clinical Trial
Official title:
A Parallel-group (2-Arm), Randomized, Double-blind, 12-week Trial to Evaluate the Efficacy and Safety of MC2-25 Cream and MC2-25 Vehicle in Subjects With Chronic Kidney Disease-associated Pruritus (CKD-aP)
The purpose of this study is to access the efficacy and safety of MC2-25 cream and MC2-25 vehicle for treatment of chronic kidney disease associated pruritus (CKD)-aP).
In this trial, subjects who fulfil all inclusion and exclusion criteria are enrolled. Eligible subjects will be randomised in a 2:1 ratio to MC2-25 cream or MC2-25 vehicle, respectively. The subjects will apply the assigned investigational medicinal product (IMP) twice daily for 12 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT03532568 -
Klotho in Chronic Kidney Disease-associated Pruritis (CKD-aP)
|
N/A | |
| Withdrawn |
NCT05625542 -
Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Hemodialysis Patients
|
||
| Not yet recruiting |
NCT06466421 -
Fexofenadine Versus Gabapentin for Uremic Pruritus in Patients on Regular Hemodialysis
|
Phase 4 | |
| Active, not recruiting |
NCT05524467 -
Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Haemodialysis Patients
|